B
Bull
Bull · 25%EXOZ
$12.90
情景价格
$7.168
-0.007 (-0.10%)收盘时
Loading chart…
- High
- 7.380
- Open
- 7.010
- VWAP
- 7.09
- Vol
- 2.78K
- Mkt Cap
- —
- Low
- 6.710
- Amount
- 19.70K
- EV/EBITDA, TTM
- 0.00
eXoZymes Inc, formerly Invizyne Technologies, Inc., is an artificial intelligence (AI) engineered enzyme that can transform sustainable feedstock into essential chemicals, medicines, and biofuels. The Company has developed a platform that offers the tools and insight to control and optimize nature’s own biological processes, enabling their partners to replace traditional chemical production methods with a new sustainable and non-polluting alternative. The Exozymes are advanced enzymes engineered using AI to thrive in a bioreactor outside of living cells.
AI analysis of eXoZymes Inc (EXOZ)
holdExozymes Inc. is currently not a strong buy due to its negative earnings and high volatility. The current price is $7.17, with a recent RSI of 64.73 indicating it is approaching overbought territory. The forward P/E ratio is 0, suggesting uncertainty in future earnings, and the company has reported consistent losses, with the latest EPS at -0.33. While the recent NIH grant of $2.02 million and a public offering raising $5.33 million provide some financial backing, the overall financial performance remains concerning. The main risk is the ongoing negative net income, which reached -2,878,614 USD in Q2 2026, indicating a need for caution before investing.
估值指标
The current forward P/E ratio for eXoZymes Inc (EXOZ) is 0.00, compared to its 5-year average forward P/E of 0.00.
Alphio AI Price Scenarios for EXOZ
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
事件时间线
资讯
8.506-24seekingalphaeXoZymes Secures $2.02M NIH Grant for Cannabinoid Research
- 8.506-08seekingalpha
eXoZymes Prices Public Offering to Raise $5.33 Million
9.504-07Yahoo FinanceMDB Capital Holdings Earnings Outlook
9.504-01Yahoo FinanceEXoZymes Inc Earnings Report Analysis and Outlook
- 9.503-31seekingalpha
eXoZymes Reports Increased FY Net Loss and Rising Expenses
EXOZ FAQ — answered by Alphio AI
eXoZymes Inc, formerly Invizyne Technologies, Inc., is an artificial intelligence (AI) engineered enzyme that can transform sustainable feedstock into essential chemicals, medicines, and biofuels. The Company has developed a platform that offers the tools and insight to control and optimize nature’s own biological processes, enabling their partners to replace traditional chemical production methods with a new sustainable and non-polluting alternative. The Exozymes are advanced enzymes engineered using AI to thrive in a bioreactor outside of living cells. It operates in the Healthcare sector.
Exozymes Inc. is currently not a strong buy due to its negative earnings and high volatility. The current price is $7.17, with a recent RSI of 64.73 indicating it is approaching overbought territory. The forward P/E ratio is 0, suggesting uncertainty in future earnings, and the company has reported consistent losses, with the latest EPS at -0.33. While the recent NIH grant of $2.02 million and a public offering raising $5.33 million provide some financial backing, the overall financial performance remains concerning. The main risk is the ongoing negative net income, which reached -2,878,614 USD in Q2 2026, indicating a need for caution before investing.
本页仅供研究参考，不构成投资建议。模型可能出错。过往表现不代表未来结果。